ABK Biomedical, a Halifax, Canada-based medical device company, raised USD30M in Series C funding.
The round was led by Santé Ventures with participation from F-Prime Capital and Eight Roads Ventures.
The company intends to use the funds to seek FDA IDE approval to execute their Eye90 microspheres® Route90 US pivotal trial and continue their clinical development programs. Additional funds will be used to clinically assess and further develop its Easi-Vue™ embolic microspheres technology, which recently received FDA 510(k) clearance.
Led by CEO Mike Mangano, ABK Biomedical is a company focused on researching, developing, and commercializing medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. The company holds intellectual property in the areas of inorganic polymer microspheres and unique administration systems. ABK Biomedical possesses advanced intellectual capital and its own R&D and manufacturing facilities for developing and commercializing unique embolotherapy products. Eye90 microspheres is considered an investigational product and is not approved for use in any regulatory jurisdiction outside of approved clinical trials.
FinSMEs
07/12/2022